GA
NAGE

Geneva Advisors’s Niagen Bioscience NAGE Stock Holding History

Geneva Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,000
Closed -$30K – 816
2016
Q3 		$30K Buy
+10,000
New +$36.7K ﹤0.01% 726

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Geneva Advisors's NAGE Position: Q4 2016 in Review

Geneva Advisors sold out of Niagen Bioscience (NAGE) in Q4 2016, closing a stake of 10,000 shares — an estimated $30K sold.

Geneva Advisors first reported a position in NAGE in Q3 2016 and held it in 1 quarter. The position peaked at $30K in Q3 2016. 52 funds tracked by Wall St. Rank hold NAGE as of Q4 2016.

  • Geneva Advisors reported no remaining Niagen Bioscience position as of Q4 2016 after selling out during the quarter.
  • Geneva Advisors sold 10,000 Niagen Bioscience shares in Q4 2016, an estimated $30K.
  • Geneva Advisors first reported a position in Niagen Bioscience in Q3 2016 and held it in 1 quarter.
  • Geneva Advisors's Niagen Bioscience position peaked at $30K in Q3 2016.
  • 52 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2016.

Based on Geneva Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.